

## Change History Table: Original – Amendments (1)

### **Amendment 1(Nov 9, 2023): BARDA BAA-23-100-SOL-00004 List of Changes:**

| <b>Amendment 1 (Nov 9, 2023)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <ol style="list-style-type: none"> <li>1. Updates to Overview Information – <ul style="list-style-type: none"> <li>• Updated Research and Development Opportunity Description</li> <li>• Updated General Market Research (TechWatch Program),</li> <li>• Updated Application Process,</li> <li>• Updated Contract and Submission Information,</li> <li>• Updated Electronic Portal Submission Instructions</li> </ul> </li> <li>2. Updates to Background</li> <li>3. Updates to Part I: Development and Technical Objectives</li> <li>4. Updates to Part IV: Pre-Submission Call and Quad Chart/Market Research Abstract Instructions (Stages 1 &amp; 2) <ul style="list-style-type: none"> <li>• Updated Figure 1. BARDA BAA Process Flow Chart</li> <li>• Updated Stage 1: Pre-submission Call with Technical POC</li> </ul> </li> <li>5. Updates to Part VI: Proposal Instructions (Stage 3) <ul style="list-style-type: none"> <li>• Updates to Stage 3: Proposal Precreation <ul style="list-style-type: none"> <li>○ Section M. Past Performance Information &amp;</li> <li>○ Vol. II, Attachment 10: Past Performance</li> <li>○ Vol. II, Attachment 11: Reason for the Proposed Award Type</li> </ul> </li> </ul> </li> <li>6. Updates to Part VII: Proposal Evaluation</li> <li>7. Updates to Area of Interest #6: Burn and Blast Medical Countermeasures <ul style="list-style-type: none"> <li>• Updated TRL Requirement</li> </ul> </li> <li>8. Updates to Area of Interest #7: Diagnostics <ul style="list-style-type: none"> <li>• Updated AOI 7.1.3 Biothreat Agent Diagnostics: Filovirus Point-of-Care and Remote Settings</li> <li>• Updated AOI 7.3.1 Influenza Home-Use Testing (for OTC or Prescription At-home)</li> <li>• Updated AOI 7.3.3 Point-of-Care Multiplex Assay for Detection of Influenza Virus</li> </ul> </li> <li>9. Updates to Area of Interest #9: IEID Therapeutics <ul style="list-style-type: none"> <li>• Added new Area of Interest 9.4 COVID-19 Monoclonal Antibody Therapeutics for Treatment</li> <li>• Updated Additional Assessment Factors for the Specific Topic AOIs</li> </ul> </li> <li>10. Suspend AOI #11: COVID-19 Immune Assay(s) Development and Implementation</li> </ol> |  |